Literature DB >> 6460442

Comparison of two parenteral diphosphonates in hypercalcemia of malignancy.

A Jung.   

Abstract

The two diphosphonates, ethane-hydroxy-diphosphonate (EHDP) and dichloromethylene-diphosphonate (Cl2MDP) were injected into 30 patients with one or multiple episodes of hypercalcemia caused by osteolytic metastases. All patients responded well to the treatment after a men delay of two days. Cl2MDP was slightly more efficient than EHDP, but there was no difference in serum calcium measured after five days of therapy with Cl2MDP or after 10 days of EHDP: in both cases, the calcium level was normal. No acute or long-term side effect has been observed. Parenteral diphosphonates may well be the treatment of first choice against malignant hypercalcemia.

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6460442     DOI： 10.1016/0002-9343(82)90813-0

Source DB:  PubMed          Journal:  Am J Med        ISSN： 0002-9343            Impact factor:   4.965


  23 in total

1.  Effect of salmon calcitonin and etidronate on hypercalcemia of malignancy.

Authors:  S Fatemi; F R Singer; R K Rude
Journal:  Calcif Tissue Int       Date:  1992-02       Impact factor: 4.333

Review 2.  Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease.

Authors:  H Fleisch
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

3.  Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure.

Authors:  M Sato; W Grasser; N Endo; R Akins; H Simmons; D D Thompson; E Golub; G A Rodan
Journal:  J Clin Invest       Date:  1991-12       Impact factor: 14.808

4.  Potentiation of calcitonin by corticosteroids during the treatment of the hypercalcaemia of malignancy.

Authors:  D J Hosking; M D Stone; J W Foote
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

5.  Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat.

Authors:  R Schenk; P Eggli; H Fleisch; S Rosini
Journal:  Calcif Tissue Int       Date:  1986-06       Impact factor: 4.333

6.  Malignant hypercalcaemia.

Authors:  J C Stevenson
Journal:  Br Med J (Clin Res Ed)       Date:  1985-08-17

7.  Quantitation of the renal effect of calcitonin in the hypercalcaemia of malignancy.

Authors:  D J Hosking; S R Heller
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

8.  Synthesis, antitumor activity, distribution and toxicity of 4-[4-[bis(2-chloroethyl)amino]phenyl]-1-hydroxybutane-1 1-bisphosphonic acid (BAD), a new lost derivative with increased accumulation in rat osteosarcoma.

Authors:  F Wingen; H Sterz; H Blum; H Möller; W Pittermann; B L Pool; H J Sinn; H Spring; D Schmähl
Journal:  J Cancer Res Clin Oncol       Date:  1986       Impact factor: 4.553

Review 9.  Drugs used in the treatment of metabolic bone disease. Clinical pharmacology and therapeutic use.

Authors:  S Patel; A R Lyons; D J Hosking
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

10.  Influence of dichloromethylene bisphosphonate on the in vitro phagocytosis of hydroxyapatite particles by rat peritoneal exudate cells: an electron microscopic and chemiluminescence study.

Authors:  P M Hyvönen; M J Kowolik
Journal:  Ann Rheum Dis       Date:  1992-02       Impact factor: 19.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.